被传奇生物“倒挂”的金斯瑞

深蓝观
09 Jan

韦晓宁 | 撰文又一 | 编辑谈母子公司“倒挂”,整个商业世界里,或许都很难找到如金斯瑞和传奇这般极致的案例:子公司传奇生物市值是金斯瑞的两倍有余。这种“倒挂”,在去年传奇收到并购邀约、强生开价达150亿美元、谈判僵持、大股东不满意价格等一系列传闻中,更加突显了。“应该一时半会儿卖不了了。”有内部人士称。金斯瑞和传奇,前者主营CXO,合成和服务是国人的专长,赚的是“辛苦钱”,有较高的确定性;后者是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10